[A24-101] Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2025
Project no.:
A24-101
Commission:
Commission awarded on 26.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with advanced non-small cell lung cancer with a rapidly accelerated fibrosarcoma isoform B V600E mutation
Result of dossier assessment:
- Patients with PD-L1 expression ≥ 50%, first-line treatment: added benefit not proven.
- Patients with PD-L1 expression < 50%, first-line treatment: added benefit not proven.
- Patients after first-line treatment: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-101
| Project no. | Title | Status |
|---|---|---|
| A20-56 | Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-61 | Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |